Acadia’s sole drug fails in depression studies
Acadia Pharmaceuticals’ Nuplazid, approved to treat symptoms of Parkinson’s disease, failed to make a difference in two depression trials, a setback in the company’s efforts to expand the use of its only approved drug.
As STAT’s Adam Feuerstein reports, Acadia ran two identical Phase 3 trials, enrolling about 300 people whose depression persists despite currently available medicines. Patients who got Nuplazid saw their depression scores improve by nine points over 15 days, while those on placebo had an 8.1-point improvement, a difference that was not statistically significant.
The disappointing result could be the end of Acadia’s ambition to win an approval in depression, and the company’s share price fell about 10% last night.
Read more.
As STAT’s Adam Feuerstein reports, Acadia ran two identical Phase 3 trials, enrolling about 300 people whose depression persists despite currently available medicines. Patients who got Nuplazid saw their depression scores improve by nine points over 15 days, while those on placebo had an 8.1-point improvement, a difference that was not statistically significant.
The disappointing result could be the end of Acadia’s ambition to win an approval in depression, and the company’s share price fell about 10% last night.
Read more.
No hay comentarios:
Publicar un comentario